TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29769088

Group type: EXPERIMENTAL
Intervention: Model of a priori consent for pragmatic comparative effectiveness trial
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Randomisation to one of two comparable drugs during a routine consultation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Electronic system randomising a patient to drug A or drug B
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Time constraints identified as a hurdle to conducting research
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Additional time for enrolment during a usual consult
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Overall acceptability of the model of a comparative effectiveness trial
Number of subjects: 23
Study: 28535202

Group type: EXPERIMENTAL
Intervention: Hypothermic ventricular fibrillation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Beating-heart technique
Number of subjects: 47
Study: 25881751

Group type: EXPERIMENTAL
Intervention: 400 mg test formulation (one 400-mg tablet)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 100 mg reference formulation (four 100-mg tablets)
Number of subjects: 35
Study: 24666765

Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5 mg titrated to 5 mg or 5 mg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) with IIEF-EF score ≥ 26
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) achieving minimal clinically important difference in IIEF-EF score
Number of subjects: 255
Study: 23017061

Group type: EXPERIMENTAL
Intervention: Hyperthermia exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19546583

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17725789

Group type: EXPERIMENTAL
Intervention: Nutrition education and physical activity intervention
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Usual health and physical education curriculum (Control)
Number of subjects: 2425
Study: 15313383

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS) + splenic artery ligation (SAL)
Number of subjects: 30
Study: 11798515

Group type: EXPERIMENTAL
Intervention: Amifostine at 740 mg/m(2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 21
Study: 9599337

Group type: EXPERIMENTAL
Intervention: D-penicillamine plus metacycline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9093983

Group type: EXPERIMENTAL
Intervention: High-volume nasogastric balanced polyethylene glycol electrolyte lavage (20 ml/kg/h) until the effluent was clear (n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-volume sodium phosphate solution (22.5-45 ml) separated by oral fluid intake (n = 14)
Number of subjects: 29
Study: 2282101

Group type: EXPERIMENTAL
Intervention: Fish oil (5 g of n‐3 fatty acids daily for 30 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (10 wheat germ oil capsules daily for 30 days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7023599

Group type: EXPERIMENTAL
Intervention: Delayed primary wound closure
Number of subjects: 122

Group type: COMPARATOR
Intervention: Primary closure with topical ampicillin powder
Number of subjects: 122

Group type: COMPARATOR
Intervention: Primary closure alone
Number of subjects: 122
Study: 30602344

Group type: EXPERIMENTAL
Intervention: Collaborative Care Model (CCM) including 10 sessions of the Life Goals self-management program and brief phone contacts by a care manager
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 238
Study: 28640159

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: tDCS-sham
Number of subjects: 30
Study: 26398887

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus high-potency statin (10mg atorvastatin or 1mg pitavastatin)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Double dose statin (20mg atorvastatin or 2mg pitavastatin)
Number of subjects: 109
Study: 25969561

Group type: EXPERIMENTAL
Intervention: 1 or 2 doses of inactivated hepatitis A vaccine (Healive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 dose of live attenuated hepatitis A vaccine (Biovac)
Number of subjects: 0
Study: 24021551

Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs (copy number variants)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs associated with known genomic disorders
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pathogenic CNVs prevalence
Number of subjects: 223

Group type: COMPARATOR
Intervention: Controls (from The Cancer Genome Atlas project)
Number of subjects: 223
Study: 21148807

Group type: EXPERIMENTAL
Intervention: supervised exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: home-based exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo pill
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: regular exercise during follow-up
Number of subjects: 202

Group type: COMPARATOR
Intervention: initial treatment group assignment
Number of subjects: 202

Group type: COMPARATOR
Intervention: antidepressant medication use during follow-up
Number of subjects: 202
Study: 18989681

Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Parenteral testosterone
Number of subjects: 21
Study: 17051456

Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis standardized extract (10 %)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketoconazole (2 %)
Number of subjects: 120
Study: 12955608

Group type: EXPERIMENTAL
Intervention: Graf ligamentoplasty
Number of subjects: 55

Group type: COMPARATOR
Intervention: ALIF with Hartshill horseshoe cage
Number of subjects: 55
Study: 11111235

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated plasma (SDP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fresh-frozen plasma (FFP)
Number of subjects: 45
Study: 9825390

Group type: EXPERIMENTAL
Intervention: Open anterior acromioplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Physiotherapy regime
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intention to treat analysis for surgery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pain-related variables
Number of subjects: 42
Study: 7903921

Group type: EXPERIMENTAL
Intervention: Methotrexate, 15 mg/wk
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2689628

Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation (Cavitron)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (untreated surfaces)
Number of subjects: 6
Study: 1095965

Group type: EXPERIMENTAL
Intervention: 30 mg S‐adenosylmethionine (SAMe) plus 6000 gamma/day of Vitamin B12
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin B12 alone
Number of subjects: 20
Study: 30933830

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (Thinking Skills for Work program)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 300
Study: 29251453

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (three different types)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-gum control
Number of subjects: 25
Study: 25498469

Group type: EXPERIMENTAL
Intervention: Wheat bran extract (WBE) 10 g/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 10 g/d)
Number of subjects: 20
Study: 23527300

Group type: EXPERIMENTAL
Intervention: CCX282-B 500 mg once daily
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: CCX282-B 250 mg once daily
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: CCX282-B 250 mg twice daily
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study: 21211500

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone SC QD
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone SC QOD
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 18353329

Group type: EXPERIMENTAL
Intervention: GnRHa treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (wait-listed volunteers)
Number of subjects: 17
Study: 16626272

Group type: EXPERIMENTAL
Intervention: First-year clinical preceptorship
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12921628

Group type: EXPERIMENTAL
Intervention: Short-term lactulose (15 - 90 ml/d for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Long-term lactulose (15 - 90 ml/d for 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (vitamin B complex only for 24 weeks)
Number of subjects: 60
Study: 10699232

Group type: EXPERIMENTAL
Intervention: Verapamil-Magnesium Oxide (V-M) combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verapamil-Placebo (V-P) combination
Number of subjects: 0
Study: 9088585

Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily for 14 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7655642

Group type: EXPERIMENTAL
Intervention: GH in daily injections (0.125 IU.kg‐1. week‐1 for the first 4 weeks and subsequently 0.25 IU.kg‐1. week‐1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 2660871

Group type: EXPERIMENTAL
Intervention: Sultamicillin (500 mg every 12 h)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Amoxicillin (500 mg every 8 h)
Number of subjects: 135
Study: 31781802

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with 0.3% ropivacaine 30 ml at mid-thigh adductor canal
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with 0.3% ropivacaine 30 ml at the thigh root-femoral nerve
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 30220048

Group type: EXPERIMENTAL
Intervention: Mechanical alignment method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Kinematic alignment method
Number of subjects: 60
Study: 29798565

Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation with rhBMP-2 and allogeneic bone grafting
Number of subjects: 48

Group type: COMPARATOR
Intervention: Short-segment pedicle screw instrumentation with allogeneic bone implanting
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 25433220

Group type: EXPERIMENTAL
Intervention: Communication skills training (8 hours)
Number of subjects: 24
Study: 24024839

Group type: EXPERIMENTAL
Intervention: Panitumumab-FOLFOX4
Number of subjects: 639

Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 639
Study: 20581700

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 2 × 6 g·d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PLA; cornstarch)
Number of subjects: 18
Study: 18070163

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 308
Study: 16599051

Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine + 4 ml hypertonic (3%) saline
Number of subjects: 93

Group type: COMPARATOR
Intervention: 1.5 mg epinephrine + 4 ml normal (0.9%) saline
Number of subjects: 93
Study: 12555836

Group type: EXPERIMENTAL
Intervention: Pain wrap dressing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 24
Study: 10674281

Group type: EXPERIMENTAL
Intervention: GHB (25 mg/kg body weight p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pirenzepine (100 mg p.o. 2 h before GHB)
Number of subjects: 0
Study: 9353508

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 200 micrograms twice daily for 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 1488321

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 2996816

Group type: EXPERIMENTAL
Intervention: Combined radio- and chemotherapy (CCNU) after surgical resection
Number of subjects: 0
Study: 31642968

Group type: EXPERIMENTAL
Intervention: Da Vinci (Xi) assisted laparoscopic resection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional laparoscopic resection
Number of subjects: 51
Study: 30063658

Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline) infusion
Number of subjects: 100
Study: 27430558

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Instruction about treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 60
Study: 24262109

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (5mg/kg) in patients undergoing retinal detachment surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous acetazolamide (5mg/kg) in patients undergoing epiretinal membrane peeling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between RD surgery and epiretinal membrane peeling groups
Number of subjects: 30
Study: 22595894

Group type: EXPERIMENTAL
Intervention: Traditional walking (n = 52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Walking with poles (n = 51)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 20489170

Group type: EXPERIMENTAL
Intervention: Intermittent TBS of the ipsilesional M1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous TBS of the contralesional M1
Number of subjects: 10
Study: 18794430

Group type: EXPERIMENTAL
Intervention: Preoperative antimicrobials (ertapenem)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Control (cefotetan)
Number of subjects: 672
Study: 15921774

Group type: EXPERIMENTAL
Intervention: Methylphenidate (therapeutic dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AD/HD children (off methylphenidate)
Number of subjects: 20
Study: 11957163

Group type: EXPERIMENTAL
Intervention: Alfentanil (induction 15 microg/kg, maintenance 15 microg/kg/hr)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Sufentanil (induction 1 microg/kg, maintenance 1 microg/kg/hr)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination of alfentanil and sufentanil (induction with alfentanil 15 microg/kg, maintenance with sufentanil 1 microg/kg/hr)
Number of subjects: 195

Group type: COMPARATOR
Intervention: All groups (A, S, AS)
Number of subjects: 195
Study: 10980844

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (streptokinase, tissue-type plasminogen activator)
Number of subjects: 200000

Group type: EXPERIMENTAL
Intervention: New thrombolytic agents
Number of subjects: 200000
Study: 8775721

Group type: EXPERIMENTAL
Intervention: Kennedy Ligament Augmentation Device (LAD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Autologous bone-patellar tendon-bone graft
Number of subjects: 48
Study: 2257866

Group type: EXPERIMENTAL
Intervention: 100 mg noscapine tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mg noscapine tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mg noscapine tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mg noscapine solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeated administration of noscapine tablets and solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Terminal half-life of noscapine
Number of subjects: 20
Study: 7149946

Group type: EXPERIMENTAL
Intervention: Integrated behavioral‐physical therapy treatment program including electromyographic feedback
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard exercise physical therapy program
Number of subjects: 37
Study: 31269001

Group type: EXPERIMENTAL
Intervention: Testing position corresponding to the second pull of the clean
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bent over torso angle
Number of subjects: 17
Study: 28498562

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 782

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Balloon Expandable (BE) valves
Number of subjects: 782

Group type: COMPARATOR
Intervention: Non-Balloon Expandable (non-BE) valves
Number of subjects: 782
Study: 25576687

Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 10 mg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Metoclopramide nasal spray 14 mg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 24142299

Group type: EXPERIMENTAL
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with standard meal (540 kcal, 21 g fat)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with light meal (390 kcal, 12 g fat)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) under fasted conditions
Number of subjects: 24
Study: 22434737

Group type: EXPERIMENTAL
Intervention: GROWTH MONITORING
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: DECREASE (GROWTH MONITORING + reducing snack foods and sugar-sweetened beverages)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: INCREASE (GROWTH MONITORING + increasing fruits, vegetables and low-fat dairy)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: TRADITIONAL (GROWTH MONITORING + decreasing sugar-sweetened beverages and increasing physical activity)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: SUBSTITUTES (GROWTH MONITORING + increasing low-fat milk consumption and reducing television watching)
Number of subjects: 182
Study: 19382202

Group type: EXPERIMENTAL
Intervention: Topical Tretinoin Chemoprevention
Number of subjects: 169
Study: 17697552

Group type: EXPERIMENTAL
Intervention: TP regimen (docetaxel combined with cisplatin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PF regimen (cisplatin combined with 5-fluorouracil)
Number of subjects: 40
Study: 15522370

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injection (0.1 ml)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo injection (subconjunctival saline)
Number of subjects: 43
Study: 11851051

Group type: EXPERIMENTAL
Intervention: Bandage A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bandage B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bandage A and B
Number of subjects: 0
Study: 9248828

Group type: EXPERIMENTAL
Intervention: Treatment program (12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Camberwell Family Interview (CFI) variables: Critical Comments, Emotional Overinvolvement, Warmth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Emotional Overinvolvement of significant other
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Critical Comments made by relatives
Number of subjects: 100
Study: 7936850

Group type: EXPERIMENTAL
Intervention: Home intervention with biweekly nurse visits beginning before delivery and extending through 18 months of life.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 60
Study: 2901839

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (less than or equal to 3 gm/day, mean 2.5)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 28689678

Group type: EXPERIMENTAL
Intervention: Sprint-Interval Exercise (SIE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous Moderate-Intensity Exercise (CMIE)
Number of subjects: 8
Study: 26883400

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate-emtricitabine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PrEP use only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PrEP and condom use
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Condom-use only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No PrEP or condom use
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Scheduled PrEP use
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Condomless receptive anal intercourse
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PrEP intake or condom use or both
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Median number of sexual partners
Number of subjects: 400
Study: 25596004

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention (diet modification, regular exercise, psychosocial consultation)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention
Number of subjects: 41
Study: 23868532

Group type: EXPERIMENTAL
Intervention: 4 h group (cumulus cell removal 4 h post-insemination)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 20 h group (cumulus cell removal 20 h post-insemination)
Number of subjects: 61
Study: 20623930

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no drink)
Number of subjects: 26
Study: 19102589

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16822114

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy plus individual‐based treatment (BCT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Individual‐based treatment only (IBT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Psychoeducational attention control treatment (PACT)
Number of subjects: 138